Engineered immune cells take on deadly childhood brain cancer
NCT ID NCT05478837
First seen Mar 16, 2026 · Last updated Apr 25, 2026 · Updated 4 times
Summary
This early-phase trial tests a new treatment called KIND T cells for people with a rare, aggressive brain tumor (diffuse midline glioma with H3.3K27M mutation). The treatment involves taking a patient's own immune cells, modifying them in a lab to recognize the tumor, and giving them back after a short course of chemotherapy. The main goals are to check safety and find the best dose in up to 12 participants aged 2 to 25.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.